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A large proportion of schizophrenia patients treated with second generation antipsychotics will develop 
Obsessive Compulsive Disorder (OCD). However, there are few studies about the impact of this 
comorbidity and who is at higher risk.  In this study of clozapine-treated patients, we aimed to determine 
the impact on outcome of clozapine-induced OCD, as well as the clinical and sociodemographic risk 
factors related to OCD-onset in clozapine patients.  We had strict and novel inclusion criteria to minimise 
mid-identification of cases. The Obsessive-Compulsive Inventory-Revised (OCI-R) was used to divide 
231 clozapine-treated patients into extreme cases of OCD (OCI ≥24 or checking subscale ≥6) versus 
non-OCD (OCI <15 and checking subscale <4). The Global Assessment of Functioning (GAF), short 
version of Warwick-Edinburgh Wellbeing scale and Clinical Global Impression for schizophrenia (CGI) 
scales were used to determine outcome. Socio-demographic information was used to identify the risk 
factors for OCD development.  We found that schizophrenia patients with OCD symptoms had a 
significantly lower patient rated wellbeing scores (p<0.001) only (no difference in clinician rated 
wellbeing scores), higher CGI positive (p<0.01) and higher CGI depressive scores (p<0.05). The only 
risk factor that reached significance level was younger paternal age at birth (p<0.05).  There is scope 
for future studies based on e.g. imaging and genetic studies to further investigate causality, and in 
improving clinician screening for OCD. 
 
 












Schizophrenia and obsessive-compulsive disorder (OCD) are frequently comorbid (McGlashan, 1984). 
Several studies have shown that schizophrenia patients treated with second generation antipsychotics 
will develop symptoms of obsessive-compulsive disorder (OCD) (Schirmbeck and Zink, 2012) with the 
proportion being around half (Fernandez-Egea et al., 2018).  To date, no replicated clinical risk factors 
have been found that help to identify vulnerable cases prior to treatment initiation. The clinical impact 
of this comorbidity on the patients’ social functioning and quality of life is largely unknown.  
Indeed, studies investigating patient outcome and level of functioning in antipsychotic induced OCD are 
sparse and need further clarification (de Haan et al., 2013; Frias et al., 2014; Kim et al., 2015; 
Mukhopadhaya et al., 2009; Seng et al., 2018; Üçok et al., 2014).  Studies have shown lower scores in 
self rated and foreign rated measures of wellbeing in those cases with antipsychotic-induced OCD 
compared to those without, with higher depressive symptoms, suicidality, hospitalisation, poorer 
physical and psychological health (de Haan et al., 2013; Kim et al., 2015; Seng et al., 2018; Üçok et al., 
2014). In addition, interpersonal relationship scores were lower in those with OCD (Üçok et al., 2014) 
and OCD cases may also show more motor symptoms (Mukhopadhaya et al., 2009). Alternatively, one 
study showed no significant difference in outcome measures (Frias et al., 2014) when using foreign 
rated measures such as the Quality of Life Scale.  Some studies which have investigated cognitive 
outcomes eg with an fMRI approach and in longitudinal studies  (Schirmbeck et al., 2013; Schirmbeck 
et al., 2015) found specific and longitudinally stable cognitive impairments associated with OCD 
comorbid schizophrenia. 
Therefore, further studies of larger and well characterised samples are needed.  
There are no reliable clinical risk factors identified for developing OCD that can help the clinician to 
predict who will be at greater risk. Indeed, even the exact mechanism and prevalence of antipsychotic-
induced OCD remain unclear. Those antipsychotics with greater anti-serotoninergic action, such as 
clozapine and olanzapine, have been more often associated with OCD onset (Poyurovsky et al., 2001; 
Schirmbeck et al., 2011). The prevalence ranges from less than 5% (Mahendran et al., 2007) to 74% 
(Schirmbeck et al., 2011), reflecting not only different methodologies used but also the differences in 
the clinical samples included. However, only a few of these studies (Fontenelle et al., 2012; Poyurovsky 
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et al., 2005) were investigating OCD risk factors specifically in cohorts of schizophrenia patients, and 
they had limited sample size. Fontenelle et al (2012) found greater severity of depression and family 
history of OCD in the cohort with comorbid OCD. Poyurovsky et al (2005) also found that relatives of 
OCD-schizophrenia patients had higher morbid risk. Recent study also pointed to the possibility of co-
prevalence of motor disorders prior to OCD development in psychotic disorders (Fineberg et al., 2017; 
Swets et al., 2018). Nevertheless, these findings need further replication in larger samples.  
 It is likely that antipsychotic-induced OCD and ‘pure’ OCD might share risk factors such as genetic, 
neurodevelopmental, immune and perinatal triggers. Demographic risk factors for ‘pure’ OCD include 
advanced maternal (Chudal et al., 2017; Steinhausen et al., 2013) and paternal age (Wu et al., 2012), 
perinatal events such as preterm birth, prolonged birth, low birth weight, breech, caesarean and forceps 
deliveries (Brander et al., 2016; Sampaio et al., 2009). Cross sectional population studies suggested 
that gender modulated  the risk of OCD onset  according  to  age with the highest risk in  adolescent 
males (Steinhausen et al., 2013) and adult females (Crum and Anthony, 1993; Fontenelle and Hasler, 
2008) . Later in life, social factors such social isolation, previous physical abuse (Grisham et al., 2011), 
maternal overprotection (Wilcox et al., 2008) and drugs, especially cocaine and cannabis use (Crum 
and Anthony, 1993) misuse were recognised as risk factors for ‘pure’ OCD.  There is a substantial body 
of work exploring genetic risk factors.  Multiple candidate genes have been found for ‘pure’ OCD 
(Mattheisen et al., 2015) and associations with candidates such as the SLC1A1 gene has been found 
in both primary and antipsychotic associated OCD. This has however been difficult to replicate in follow 
up studies across ethnicities (Schirmbeck and Zink., 2013). In addition, genes have been found which 
share polygenic risk with both OCD and schizophrenia (Costas et al., 2016) 
One potential explanation of the lack of clinical risk factors for developing OCD in antipsychotic-treated 
patients could be the mis-identification of cases. In a recent report by Fernandez-Egea et al (2018) 
using a large cohort of clozapine treated patients, we identified a few factors that might have acted as 
confounders in prior studies. For instance, we found rising OCD prevalence and checking compulsion 
to be associated with increasing years of treatment. Development of OCD in this cohort could be a 
combination of underlying vulnerability and anti-psychotic treatment, so it is possible that a patient 
without OCD after 5 years of treatment might still be mis-identified as non-case despite going on to 
develop OCD later. We also found that psychosis severity correlated with OCD and obsessions severity 
which could potentially over-represent OCD cases in those more floridly psychotic. Such distinctions 
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have barely been considered in prior studies of the sociodemographic and clinical risk factors of 
antipsychotic-induced OCD.  
Our aims for this study were to a) determine if comorbid OCD is associated with a poorer outcome 
measures such as global functioning and subjective wellbeing, and b) identify the clinical and 
sociodemographic factors associated with antipsychotic-induced OCD. We used the electronic records 
of a large cohort of clozapine treated patients who were carefully clinically phenotyped, including using 
standardised scales for OCD. In order to maximise the group differences, decided on a strategy of 
selecting the two ends of the clinical phenotype (with or without OCD) of clozapine-treated patients as 
this drug is more strongly associated with OCD-onset. We then performed a whole sample analysis as 
a confirmatory step. 
1. Experimental procedures 
It is of note that we covered the prevalence and complex phenomenology of obsessions and 
compulsions in clozapine-treated patients in a previous work(Fernandez-Egea et al., 2018). Here, we 
use the term OCD to define these phenomena, albeit acknowledging the open debate about its 
pathophysiology and correct terminology.  
Study design  
This is a cross sectional, single centre study of a cohort of clozapine treated patients at the 
Cambridgeshire and Peterborough NHS Foundation Trust. The study included anonymised electronic 
clinical records of all cases from August 2015 to April 2018, embedded in an ethically approved 
database for research and clinical purposes (13/EE/0121). All cases were reviewed by the same care 
consultant (EFE). 
Participants  
The clinical records of all schizophrenia patients treated with clozapine were initially included in this 
study.  
Assessment 
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Routine clinical assessments are described elsewhere (Fernandez-Egea et al., 2018) and include full 
psychiatric history, comprehensive mental state examination, current medication list, smoking habit, 
legal and illegal drug history, early life history, clozapine treatment length and side effects assessment 
and physical health assessment. Among others, psychopathological scales included assessment for 
general functioning [Global Assessment of Functioning (GAF) ](Haro et al., 2003), short version of the 
Warwick-Edinburgh Wellbeing Scale [SWEWBS](Brown et al., 2016) and symptom severity using the 
Clinical Global Impression (CGI) for Schizophrenia (Busner and Targum, 2007) which includes 5 
domains (positive, negative, cognitive, and depression) rating from 1 to 7 for absence to extreme 
severity.  
The Obsessive-Compulsive Inventory revised version (OCI-R) was the questionnaire used for 
determining cut off scores for OCD diagnosis(Foa et al., 2002). This widely used 18 item self-rated 
questionnaire is done annually in these patients. Each question has a five-point Likert-type score 
measuring the degree of distress experienced with common OCD phenomena (not at all to extremely). 
It also contains six sub-scales measuring severity for obsessions, checking, washing, hoarding, 
neutralising and ordering. A cut-off of 21 for the total scale or above 5 for subscales is considered for 
OCD diagnosis(Foa et al., 2002). In a previous study, we showed that OCI-R and its six-factor 
component had a valid goodness-of-fit and structure in clozapine-treated patients.(Fernandez-Egea et 
al., 2018) 
Inclusion and exclusion criteria 
The exclusion criteria were: 1) cases with no primary psychotic disorder (off label use of clozapine), 2) 
those cases in which documented OCD predated clozapine use and 3) and cases that neither showed 
clear OCD symptoms nor had a clear absence of OCD symptoms. The latter criterion was set to 
maximise the group differences and reduce false positives and we selected the two ends of the clinical 
phenotype (with and without OCD). We considered the duration of treatment, severity of the obsessive-
compulsive symptoms and the checking symptoms severity, as they are the most commonly reported 
symptoms. Length of clozapine treatment was relevant as some might have not yet expressed the 
vulnerability. In this study, OCD was considered if an OCI-total score ≥24 or checking subscale ≥6 
regardless of treatment duration. Whereas an OCI-total score <15, checking subscale <4, no treatment 
for OCD, and a treatment duration longer than 5 years for the non-OCD group were considered. To 
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note, we used a more strict score criteria for OCD, of 24 instead of 21, in order to include cases with 
uncontroversial OCD diagnosis.   
Statistical analysis 
All statistical analyses were conducted using SPSS v23.0, with a two-tail 0.05 significance level and R 
studio Version 1.0.136. Data are presented as mean (M) and standard deviation (SD).  Two 
independent data analyses were performed as follows: the impact of developing antipsychotic-
induced OCD was assessed comparing global functioning and subjective wellbeing using a series of 
Multivariate ANOVAs (MANOVA). To identify the risk factors for developing OCD, we used the 
following list of potential risk factors for both antipsychotic-induced OCD and general OCD literature: 
paternal and maternal age, birth weight, hand dominance, family history of psychosis and OCD, age 
at presentation of schizophrenia, gender, treatment dose and duration, smoking habit, comorbidities 
with other psychiatric disorders and whether or not the psychosis was initially triggered by drug use. 
For this part of the analysis, we used 2-tailed Students t-tests for normally distributed continuous data, 
Mann–Whitney U test for not normally distributed continuous data and χ2 test for categorical variables 
and a MANOVA according to the analysis needs. A confirmatory analysis was conducted with the 




The database contained two hundred thirty-one patients on clozapine with primary diagnosis of non-
affective psychosis. Of those, seventy-four were missing the OCI-R scores and were not included in 
the analysis. Eight patients were excluded due to prior OCD diagnosis. One patient was excluded due 
to confirmed learning disability.  
Sixty-three patients were excluded for having an OCI-R total score between 15-24 and/or a checking 
subscale score between 4-6.  The final sample of 85 participants consists of 29 schizophrenia patients 
without OCD symptoms (4 females, 25 males; mean age = 45.24, SD =12.66, range: 27–70 years) and 
56 patients with OCD symptoms (14 females, 42 males; mean age 48.29 SD = 9.76, range: 29–
69 years).  Eleven out of 56 patients in the OCD group and 6 out of 29 patients in the non-OCD group 
were missing their parent’s age at birth. Two participants in the non-OCD group were missing the hand 
dominance data. 11 patients in the non-OCD group and 24 in the OCD group did not know their birth 
weights. 17 participants without OCD and 31 with OCD symptoms could not provide their family history. 
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Table 1 shows the descriptive statistics and the significance values for differences between OCD and 
non-OCD groups for all variables. 
 
Impact of antipsychotic-induced OCD in patient rated wellbeing and functioning  
A series of MANOVA were conducted to assess the impact of OCD versus no-OCD (independent 
variable) on the GAF, CGI-Positive, CGI-Negative, CGI-Depressive, CGI-Cognitive, CGI-Overall, and 
the Wellbeing scores. 
The results (figure 1) showed a significant effect of group on wellbeing scores, F(1, 83) = 22.017, p < 
0.001. Patients with OCD symptoms had a lower wellbeing score (M=21.95, SD=4.33) compared with 
the non-OCD group (M=27.10, SD=5.60). The presence of OCD also had a significant effect on the 
CGI-Positive scores, F(1) = 18.48, p < 0.01). There were higher scores in the OCD-schizophrenia group 
(M=3.0, SD=1.44) compared with the schizophrenia group without OCD (M=2.0, SD=1.47). In addition, 
the MANOVA results showed that belonging to OCD versus non-OCD group also influenced the CGI-
Depressive scores significantly, F(1) = 4.046, p < 0.05, with higher depressive scores in schizophrenia-
OCD group (M=2.8, SD=1.16) compared with the other group without OCD (M=2.97, SD=1.57). There 
was no effect of group on the GAF and the CGI-Negative scores. Table 1 shows the MANOVA results 
for all variables.  
 
Risk factors for developing OCD  
Next, we were interested to understand the clinical and sociodemographic factors associated with 
antipsychotic-induced OCD. A 2-tailed Students t-test was used to examine the impact of parents’ age, 
treatment dose and duration on the OCD symptoms development since these variables were 
continuous and normally distributed. 
There were significant differences between groups for the father’s age at birth and the treatment dose. 
Significantly more patients with OCD symptoms had a younger father at birth (M = 29.60, SD = 6.11) 
and a higher treatment dose (M=349.5 ,SD=123.35)  compared to those without OCD symptoms who 
had an older father (M=33.52 , SD=8) and were on a lower dose (M=264.66 , SD=144), the t-test results 
are respectively t(66) = 2.25, p = 0.028 and t(83) = 2.84, p < 0.01. However, there was no significant 
   
 
9
difference between groups for the number of years they have been treated with clozapine t(83) = -
0.062, p = ns.  
A Mann–Whitney U test was performed to assess the associations between belonging to each group 
and the mother’s age at birth and the patient’s age at first presentation of psychosis since these 
variables were continuous and not normally distributed. The mother’s age at birth was lower in the OCD 
group (M = 27.02; SD = 5.06) compared with the non-OCD schizophrenia group (M = 30.17; SD = 6.33). 
However, this difference did not reach significance, U =370.5, p = 0.056. There was no significant 
difference for the age at presentation between the two groups U =742, p = ns.  
The χ2 test was performed to assess the differences between group with gender, comorbidities with 
other psychiatric disorders, impact of a lower birth weight, family history of psychosis and OCD, hand 
dominance, current smoking and whether the psychosis was triggered by drug use, as these variables 
were categorical in nature. None of these associations reached significance (see Table 1).  
A multiple linear regression was calculated as a second confirmatory analysis using the whole sample 
of patients with OCI total scores as dependant variable and all the risk factor variables described above. 
The best model with the highest adjusted-R2 was the one with years on clozapine, gender, father’s age 
at birth, family history of psychosis and OCD, treatment dose of clozapine and smoking habit as 
independent variables. A significant regression equation was found (F(12,110) = 1.885, p < .5), with an 
adjusted-R2 of 0.08. Only treatment dose was a significant predictor of the OCI total score (t (110) = 
2.949, p < 0.001). The family history of psychosis together with a first degree relative OCD diagnosis 
seem to also be associated with higher scores of the OCI total, however, it did not reach significance 
level (t (110) = 1.853, p = 0.06). 
  
Discussion 
In this study, we found that schizophrenia patients with clozapine-induced OCD had a lower subjective 
wellbeing score but not a diminished clinician-rated level of functioning. In our sample, younger paternal 
age and higher clozapine dose were significant risk factors for developing OCD. Thus, we identified 
fewer risk factors for OCD onset in compared to previous studies, which could be due to our very 
selective patient selection process. It is of note that we set restrictive inclusion criteria that considered 
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OCI-R total score, checking subset, and length of treatment. This strategy was adopted to minimise the 
mis-identification of cases. Indeed, sixty-three patients (more than a quarter of all the cases) were 
excluded due to having mid-range OCI-scores, who might have not developed clinical OCD due to short 
exposure to clozapine.  
The multiple linear regression analysis in the whole sample differed in some respects. It still confirmed 
that role of treatment dose seems to have a significant impact on the OCI total scores.  Nevertheless, 
we need to be cautious with this analysis, as when using the whole sample the risk of mis-identification 
of cases was high. For example, a mid-range OCI score could actually be a case due to not yet being 
on clozapine long enough to manifest, or a non-case due to a falsely high total OCI-R score from florid 
psychotic symptoms. In addition, there are likely multiple other factors involved in the development of 
OCD in schizophrenia, not least of which are genetic factors (Schirmbeck and Zink, 2013) which have 
not been explored in this paper.  
Patients with schizophrenia who develop OCD showed worse functioning as measured by significantly 
lower wellbeing scores (as subjectively scored by the patients themselves). This is in concordance with 
previous work (de Haan et al., 2013; Seng et al., 2018; Üçok et al., 2014), which used self rated scales 
to assess quality of life. In our study, a clinician-scored GAF scale was also used. Notably, there was 
no significant difference between groups. The previous study not finding any association between OCS 
and outcome measures also used  clinician rated quality of life measure (Frias et al., 2014).  However, 
the clinician rated CGI scale showed increased depressive scores in the OCD cohort, which could be 
an indicator of the impact of the additional diagnosis on patient wellbeing or potentially due to the greater 
degree of positive symptoms as they also had higher CGI-positive scores.  There is an indication that 
clinicians can be unaware of the degree to which having OCD can negatively impact the patients’ lives. 
The lack of awareness can therefore lead to patients not receiving adequate treatment for their OCD 
symptoms. The reasons for a lack of insight could be inadequate screening, of both patient's OCD 
symptoms and also their personal concerns. Increasing the awareness of the comorbidity as well as 
the routine use of screening tools might be of help to identify and treat these patients.  
In the OCD group, we found higher CGI-positive scores, implying greater degree of positive symptoms 
of schizophrenia in the OCD cohort compared to non-OCD group. This could be consistent with a 
cognitive theory of the development of OCD in anti-psychotic induced schizophrenia (Fernandez-Egea 
   
 
11
et al., 2018). We have previously found that checking was the most prevalent symptom that developed 
after clozapine treatment.  Pending of further replication, it was proposed that there may be two OCD 
stages in clozapine-treated psychosis. The initial goal directed checking behaviour in OCD was 
triggered by positive symptoms of psychosis i.e. checking due to delusional hypervigilance. Once the 
obsessional positive symptoms are improved, and perhaps due to the potent clozapine-induced anti-
serotoninergic action, the residual checking phenomenon became part of the habit, developing a full 
OCD.  Therefore, whether a patient has positive symptoms initially, could affect how likely they are to 
develop ongoing checking behaviour. Those exhibiting mainly positive schizophrenia symptoms at the 
beginning being more likely to have it incorporated into the checking behaviour of OCD. There was a 
trend for type of initial presentation, with greater proportion of schizophrenia-OCD cohort having 
presented with positive symptoms; however, the association did not attain statistical significance.   
Younger paternal age was the only significant socio-demographic factor associated with the onset of 
OCD symptoms in patients with schizophrenia, which is a novel finding. It is in contrast with the only 
existing study that showed an increased OCD risk with increasing paternal age (Wu et al., 2012). 
However, this study did not study OCD development in existing schizophrenia. 
The higher treatment doses of clozapine in the OCD group replicates previous findings (Baytunca et 
al., 2017; Fernandez-Egea et al., 2018) and remained consistent in confirmatory multilinear regression 
analysis.  This could have various explanations such as biological sex, where males require higher 
doses, and smoking status, where smokers require higher doses.  However, there were no significant 
differences in sex or smoking status (current or historical) between groups. Previous studies have 
shown an association between OCD severity and clozapine dose( Mukhopadhaya et al., 2009; 
Schirmbeck et al., 2011) . When comparisons are made between the more representative plasma 
clozapine levels and OCD symptoms, which would remove the issues of compliance and different 
pharmacokinetics, the association no longer remains significant (Fernandez-Egea et al., 2018; 
Schirmbeck et al., 2011). The severity of positive symptoms could be a confounding factor in the 
relationship between clozapine dose and OCD severity, due to more severe symptoms of schizophrenia 
in the OCD group leading to increased requirement of clozapine.  
 
Limitations 
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There were strengths in this study, such as the comparatively larger number of subjects available, and 
the use of many well validated scoring scales. However as this is a cross sectional study, we are unable 
to take a longitudinal view to explore causality. We were also unable to carry out genetic studies or 
neuro-imaging, due to the origin of the data being from the routine clinic work. These points can however 
be used in preparation for future studies e.g. into genetic associations which has been planned as a 
follow up study to explore causality. Assessing family history in our sample was also difficult, due to the 
information source being the patients themselves.  Patients were presenting to clinic with symptoms of 
psychosis, so their recollections may not have been an accurate representation.  This could explain 
why our findings did not replicate some of the previous results. (Fontenelle et al., 2012; Poyurovsky et 
al., 2005)  
 
Conclusion 
In conclusion, an additional comorbidity of OCD significantly lowers the wellbeing of schizophrenia 
patients on subjective scales, especially those with higher positive and higher depressive symptoms. It 
is clear that there is also an incongruence between physician reported and patient reported quality of 
life results. Further research could be warranted, with increased clinician screening for OCD in reviews, 
and using both types of tools in screening as a goal in the clinical setting.  With regards to risk factors, 
there were very few specific markers, either clinical or socio-demographic which could account for the 
development of OCD in schizophrenia. Although paternal age and clozapine dose were significant, their 
effects did not account for enough of the difference between groups.  The possibility of a positive family 
history being associated with OCD development shows there is scope for future studies based on 
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Table.1 Description of the risk factors 
 OCD Non-OCD p 
N 56 29  
Age at presentation (M ± SD) 21.36 ± 4.9 21.34 ± 5.9 .518 
Gender male (%) 75 86.2 .275 
Father’s age at birth (M ± SD) 29.6 ± 6.11 33.52 ± 8 .028* 
Mother’s age at birth (M ± SD) 27.02 ± 5.06 30.17 ± 6.33 .056 
Treatment dose (M ± SD) 349.55 ± 
123.35 
264.66 ± 144 .006** 
Treatment duration (M ± SD) 16 ± 7.7 16.14 ± 6.24 .951 
Low birth weight (%) 8.9a 6.9a .786 
Current smoking (%) 32.1 31 .56 
Comorbidities (%)   .667 
     Depression/schizoaffective disorder 10.7 6.9  
     Anxiety/panic/phobia 5.4 10.3  
     PTSD 0 3.4  
     Drug/alcohol misuse 5.4 10.3  
Family history (%)   .728 
     Psychosis/bipolar disorder in 1st degree 
relatives 
12.5 24.1  
     OCD/affective disorders in 1st degree 
relatives 
14.3 10.3  
     Psychosis/bipolar disorder in 2nd degree 
relatives 
10.7 6.9  
Hand dominance (%)   .261 
     Right 76.8 69  
     Left 17.9 20.7  
     Both 5.4 3.4b  
Psychosis triggered by drug use (%) 46.4 48.3 .733 
     Type of presentation (%)   .052 
     Hallucination/delusion 94.6 79.3  
     Psychosis part of mania/affective disorder 1.8 10.3  
     Non-positive presentation 0 6.9  
     Unknown 3.6 3.4  
Note: p represents p-significance group differences (OCD vs non-OCD) using student’s t for father’s age at birth, 
treatment dose and duration, Mann–Whitney U  for mother’s age at birth and age at presentation, and the χ2 test for 
gender, low birth weight (< 2500 g), current smoking, comorbidities, family history, hand dominance, psychosis 
triggered by drug use, and type of presentation . a) 24 out of 56 patients in the OCD group and 11 out of 29 patients 
in the non-OCD group did not have their birth-weight information. b) handedness information of two patients in the 
non-OCD group were missing. The significance levels of p < 0.05 and p < 0.01 are indicated with one and two stars 
respectively.  
 





















Figure.1 A) Shows the average scores on different subsets of the Clinical Global Impression (CGI) scale. 
B) Shows the average scores on the Global Assessment of Functioning (GAF) rated by clinicians and the 
Wellbeing scores rated by patients themselves. The Wellbeing scores are converted to percentages. The 
significance levels of p < 0.05, p < 0.01, and p < 0.001 are indicated with one, two and three stars 
respectively. 
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